Comorbidities in Canadian patients with hereditary angioedema: a quantitative survey study
Abstract Background Evidence linking hereditary angioedema (HAE) to the potential association of developing other comorbidities, and how it is affected by HAE treatment is needed. The objective of this study is to identify comorbidities and measure the prevalence in HAE patients, compared to the pre...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-03-01
|
| Series: | Allergy, Asthma & Clinical Immunology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13223-025-00953-8 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850054335622283264 |
|---|---|
| author | Paul K. Keith Gina Lacuesta Dawn Goodyear Stephen D. Betschel Belinda Yap Marie-France Dansereau Nataly Tanios Rami El-Sayegh Maye Machnouk Hachem Mahfouz Adriana Martin Susan Waserman |
| author_facet | Paul K. Keith Gina Lacuesta Dawn Goodyear Stephen D. Betschel Belinda Yap Marie-France Dansereau Nataly Tanios Rami El-Sayegh Maye Machnouk Hachem Mahfouz Adriana Martin Susan Waserman |
| author_sort | Paul K. Keith |
| collection | DOAJ |
| description | Abstract Background Evidence linking hereditary angioedema (HAE) to the potential association of developing other comorbidities, and how it is affected by HAE treatment is needed. The objective of this study is to identify comorbidities and measure the prevalence in HAE patients, compared to the prevalence in the general population using multiple Canadian sources when available. Methods A quantitative survey design via a self-administered anonymous online questionnaire was conducted from October 13, 2022, to January 11, 2023. Respondents were individuals with HAE, enrolled in the CSL Behring patient support program (CSL Behring PLUS+; PSP). Results This study included 123 patients (81% female; 60% HAE-1/HAE-2, 24% HAE Normal C1-INH (nC1-INH), 16% unsure of HAE type; 85% of patients were on long-term prophylaxis plus on-demand). Patients reported using the following HAE treatments: C1-esterase inhibitor (subcutaneous or intravenous), lanadelumab, icatibant, danazol, and tranexamic acid. Respondents (69%) reported at least one: autoimmune condition, asthma, or allergy. Reported autoimmune conditions (psoriasis, rheumatoid arthritis, inflammatory bowel disease, chronic urticaria, lupus, and psoriatic arthritis) were much higher than the general population (31% versus 5–8%). Patient-reported allergies were two times higher than the general population (54% versus 27%; i.e., aeroallergens) and asthma rates nearly two times higher than the general population (17% versus 8–11%). Conclusion This cohort of HAE patients, most of whom were on prophylaxis, reported an increased prevalence of certain comorbidities compared to the general Canadian population. Healthcare professionals should be aware of the potentially increased risk of autoimmune conditions, allergies, and asthma in patients with HAE. |
| format | Article |
| id | doaj-art-a378df82da4c40d3976b114520f039b5 |
| institution | DOAJ |
| issn | 1710-1492 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | BMC |
| record_format | Article |
| series | Allergy, Asthma & Clinical Immunology |
| spelling | doaj-art-a378df82da4c40d3976b114520f039b52025-08-20T02:52:17ZengBMCAllergy, Asthma & Clinical Immunology1710-14922025-03-0121111110.1186/s13223-025-00953-8Comorbidities in Canadian patients with hereditary angioedema: a quantitative survey studyPaul K. Keith0Gina Lacuesta1Dawn Goodyear2Stephen D. Betschel3Belinda Yap4Marie-France Dansereau5Nataly Tanios6Rami El-Sayegh7Maye Machnouk8Hachem Mahfouz9Adriana Martin10Susan Waserman11Department of Medicine, McMaster UniversityDalhousie UniversityDivision of Hematology and Hematologic Malignancies, Department of Medicine, University of CalgaryDepartment of Clinical Immunology and Allergy, University of TorontoCencora, Innomar Strategies IncCencora, Innomar Strategies IncCencora, Innomar Strategies IncCencora, Innomar Strategies IncCSL Behring Canada IncCSL Behring Canada IncCSL Behring Canada IncDepartment of Medicine, McMaster UniversityAbstract Background Evidence linking hereditary angioedema (HAE) to the potential association of developing other comorbidities, and how it is affected by HAE treatment is needed. The objective of this study is to identify comorbidities and measure the prevalence in HAE patients, compared to the prevalence in the general population using multiple Canadian sources when available. Methods A quantitative survey design via a self-administered anonymous online questionnaire was conducted from October 13, 2022, to January 11, 2023. Respondents were individuals with HAE, enrolled in the CSL Behring patient support program (CSL Behring PLUS+; PSP). Results This study included 123 patients (81% female; 60% HAE-1/HAE-2, 24% HAE Normal C1-INH (nC1-INH), 16% unsure of HAE type; 85% of patients were on long-term prophylaxis plus on-demand). Patients reported using the following HAE treatments: C1-esterase inhibitor (subcutaneous or intravenous), lanadelumab, icatibant, danazol, and tranexamic acid. Respondents (69%) reported at least one: autoimmune condition, asthma, or allergy. Reported autoimmune conditions (psoriasis, rheumatoid arthritis, inflammatory bowel disease, chronic urticaria, lupus, and psoriatic arthritis) were much higher than the general population (31% versus 5–8%). Patient-reported allergies were two times higher than the general population (54% versus 27%; i.e., aeroallergens) and asthma rates nearly two times higher than the general population (17% versus 8–11%). Conclusion This cohort of HAE patients, most of whom were on prophylaxis, reported an increased prevalence of certain comorbidities compared to the general Canadian population. Healthcare professionals should be aware of the potentially increased risk of autoimmune conditions, allergies, and asthma in patients with HAE.https://doi.org/10.1186/s13223-025-00953-8Hereditary AngioedemaAutoimmuneAllergyAsthmaC1 inhibitorComorbidities |
| spellingShingle | Paul K. Keith Gina Lacuesta Dawn Goodyear Stephen D. Betschel Belinda Yap Marie-France Dansereau Nataly Tanios Rami El-Sayegh Maye Machnouk Hachem Mahfouz Adriana Martin Susan Waserman Comorbidities in Canadian patients with hereditary angioedema: a quantitative survey study Allergy, Asthma & Clinical Immunology Hereditary Angioedema Autoimmune Allergy Asthma C1 inhibitor Comorbidities |
| title | Comorbidities in Canadian patients with hereditary angioedema: a quantitative survey study |
| title_full | Comorbidities in Canadian patients with hereditary angioedema: a quantitative survey study |
| title_fullStr | Comorbidities in Canadian patients with hereditary angioedema: a quantitative survey study |
| title_full_unstemmed | Comorbidities in Canadian patients with hereditary angioedema: a quantitative survey study |
| title_short | Comorbidities in Canadian patients with hereditary angioedema: a quantitative survey study |
| title_sort | comorbidities in canadian patients with hereditary angioedema a quantitative survey study |
| topic | Hereditary Angioedema Autoimmune Allergy Asthma C1 inhibitor Comorbidities |
| url | https://doi.org/10.1186/s13223-025-00953-8 |
| work_keys_str_mv | AT paulkkeith comorbiditiesincanadianpatientswithhereditaryangioedemaaquantitativesurveystudy AT ginalacuesta comorbiditiesincanadianpatientswithhereditaryangioedemaaquantitativesurveystudy AT dawngoodyear comorbiditiesincanadianpatientswithhereditaryangioedemaaquantitativesurveystudy AT stephendbetschel comorbiditiesincanadianpatientswithhereditaryangioedemaaquantitativesurveystudy AT belindayap comorbiditiesincanadianpatientswithhereditaryangioedemaaquantitativesurveystudy AT mariefrancedansereau comorbiditiesincanadianpatientswithhereditaryangioedemaaquantitativesurveystudy AT natalytanios comorbiditiesincanadianpatientswithhereditaryangioedemaaquantitativesurveystudy AT ramielsayegh comorbiditiesincanadianpatientswithhereditaryangioedemaaquantitativesurveystudy AT mayemachnouk comorbiditiesincanadianpatientswithhereditaryangioedemaaquantitativesurveystudy AT hachemmahfouz comorbiditiesincanadianpatientswithhereditaryangioedemaaquantitativesurveystudy AT adrianamartin comorbiditiesincanadianpatientswithhereditaryangioedemaaquantitativesurveystudy AT susanwaserman comorbiditiesincanadianpatientswithhereditaryangioedemaaquantitativesurveystudy |